2. Academic Validation
  3. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity

A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity

  • Cell Discov. 2020 Jul 28;6(1):49. doi: 10.1038/s41421-020-0181-z.
Adam M Burgoyne # 1,  Kendra R Vann # 2,  Shweta Joshi 3,  Guillermo A Morales 4,  Francisco M Vega 3 5,  Alok Singh 3,  Dhananjaya Pal 3,  Aran B Merati 1,  Tatiana G Kutateladze 2,  Donald L Durden 3 4
Affiliations

Affiliations

  • 1 Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA USA.
  • 2 Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO USA.
  • 3 Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA USA.
  • 4 SignalRx Pharmaceuticals, San Diego, CA USA.
  • 5 Department of Cell Biology, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain.
  • # Contributed equally.
PMID: 32793389 DOI: 10.1038/s41421-020-0181-z
Keywords

Cancer therapy; Epigenetics; X-ray crystallography.

Figures
Products